2022
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatients
2017
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. Journal Of Hepatology 2017, 67: 585-602. PMID: 28323126, DOI: 10.1016/j.jhep.2017.03.006.Peer-Reviewed Original ResearchConceptsLiver transplantationHCV infectionConsensus statementUse of DAAsLiver transplant candidatesLiver transplant recipientsSevere renal failureRemarkable clinical improvementTransplant recipientsClinical improvementLT candidatesRenal failureTransplant candidatesDisease recurrenceNative liverUnusual complicationTransplant fieldDrug interactionsHCV- graftsWaiting listAntiviral agentsRecipientsHCVPatientsGraft
2015
Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort
Belli LS, Romagnoli R, Nardi A, Marianelli T, Donato F, Corradini SG, Iemmolo RM, Morelli C, Pasulo L, Rendina M, De Martin E, Ponziani FR, Volpes R, Strazzabosco M, Angelico M, Investigators L. Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. Digestive And Liver Disease 2015, 47: 689-694. PMID: 26055490, DOI: 10.1016/j.dld.2015.04.006.Peer-Reviewed Original ResearchConceptsRecipient female genderGraft lossFemale genderLiver transplantationRisk factorsEnd-stage liver disease (MELD) scoreFive-year graft survivalStage liver disease scoreOutcome of HCVSevere HCV recurrenceChronic hepatitis CHCV-positive patientsLiver Disease scoreHepatitis C virusHCV recurrenceGraft outcomeGraft survivalHepatitis CPortal thrombosisTransplant recipientsLiver graftsIndependent determinantsRetrospective studyC virusMatch cohort
2008
Incidence and Management of Colorectal Cancer in Liver Transplant Recipients
Nishihori T, Strazzabosco M, Saif MW. Incidence and Management of Colorectal Cancer in Liver Transplant Recipients. Clinical Colorectal Cancer 2008, 7: 260-266. PMID: 18650194, PMCID: PMC3755274, DOI: 10.3816/ccc.2008.n.033.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsTransplant recipientsColorectal cancerLiver transplantationPatient populationColon cancerDe novo colorectal cancerDe novo malignanciesLong-term immunosuppressionMetastatic colorectal cancerPrimary sclerosing cholangitisInflammatory bowel diseaseMajor health concernChronic rejectionNovo malignanciesProlonged immunosuppressionSclerosing cholangitisPosttransplantation periodBiologic agentsBowel diseaseCombination chemotherapyProphylactic colectomyOverall incidenceCommon malignancyLymphoproliferative disease
1998
Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery
Iemmolo R, Rossanese A, Rotilio A, Mattisi G, Gerunda G, Merenda R, Neri D, Crepaldi G, Strazzabosco M. Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery. Journal Of Hepatology 1998, 28: 518-522. PMID: 9551693, DOI: 10.1016/s0168-8278(98)80329-2.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsLiposomal amphotericin BTransplant recipientsCerebral aspergillosisAmphotericin BLife-threatening complicationsLiposomal amphotericin B.Complication-free survivalRisk of recurrenceSystemic side effectsAspergillus fumigatus infectionLong-term survivalSurgical excisionCase reportFumigatus infectionLimited efficacyCerebrospinal fluidSide effectsMortality rateAmphotericin B.AspergillosisRecipientsSurvivalTreatmentFirst report
1997
Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients
Strazzabosco M, Corneo B, Iemmolo R, Menin C, Gerunda G, Bonaldi L, Merenda R, Neri D, Poletti A, Montagna M, Del Mistro A, Faccioli A, D'Andrea E. Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients. Journal Of Hepatology 1997, 26: 926-934. PMID: 9126809, DOI: 10.1016/s0168-8278(97)80262-0.Peer-Reviewed Original ResearchConceptsPost-transplant lymphoproliferative diseaseLiver transplant recipientsOrthotopic liver transplant recipientsLymphoproliferative diseaseTransplant recipientsDonor originB lymphocytesDonor B lymphocytesEBV-specific probesPost-transplant lymphomaOrthotopic liver transplantEpstein-Barr virus sequencesSolid organ transplantationPossible risk factorsLympho-proliferative diseaseNeoplastic B cellsLiver transplantEBV DNAHepatic hilumProspective studyHodgkin's lymphomaPolymerase chain reactionPotential complicationsRisk factorsReal incidence